Multiple Sclerosis

Early intervention with ocrelizumab resulted in a 35% reduction of risk in individuals with RMS who needed a walking aid over 7 and a half years.

The 5 largest specialty therapeutic groups—oncology, autoimmune, immunology, HIV, and multiple sclerosis—will account for 74% of specialty spending growth over the next five years.

Although there was a numerical difference between the mean number of new or newly enlarging T2 hyperintense lesions at week 72 of 0.05 (Q4W) and 0.20 (Q6W), this difference was not clinically meaningful in the context of the full data, according to the investigators.